Compared to Estimates, Cardinal (CAH) Q4 Earnings: A Look at Key Metrics

Cardinal Health (CAH) reported Q4 2025 revenue of $60.16 billion, a 0.5% year-over-year increase, which missed the Zacks Consensus Estimate by 0.84%. However, the company delivered an EPS of $2.08, surpassing the $2.03 consensus by 2.46%. This mixed performance, with a revenue miss but an earnings beat, reflects varied segment results, including a slight revenue shortfall in its Pharmaceutical and Specialty Solutions division. Despite recent stock underperformance against the S&P 500, CAH holds a Zacks Rank #2 (Buy), suggesting potential near-term outperformance.

Analysis

Cardinal Health (CAH) presented a mixed financial picture for its fourth quarter ending June 2025, characterized by a bottom-line beat but a top-line miss. The company reported total revenue of $60.16 billion, representing a marginal 0.5% year-over-year increase but falling 0.84% short of the Zacks Consensus Estimate. In contrast, earnings per share of $2.08 marked a significant 13% increase from the prior year's $1.84 and surpassed analyst expectations by 2.46%. A deeper look into segment performance reveals the source of this divergence: the core Pharmaceutical and Specialty Solutions segment, which accounts for the vast majority of sales, saw revenue decline 0.4% YoY to $55.37 billion, missing its estimate. This segment's profit also fell short of expectations. Conversely, the smaller Medical Products and Distribution and "Other" segments demonstrated profitability strength, with both beating their respective segment profit forecasts. The "Other" segment was a notable outperformer with 37.3% YoY revenue growth. This operational performance has been met with recent market skepticism, as the stock has returned -2.5% over the past month, underperforming the S&P 500 composite's +2% gain, though it currently holds a Zacks Rank #2 (Buy).

Key Decisions for Investors

• Investors should weigh the robust 13% year-over-year EPS growth and positive earnings surprise against the stagnating top-line revenue and the specific weakness in the core Pharmaceutical segment.
• Monitor the performance of the Pharmaceutical and Specialty Solutions division closely, as any turnaround in this largest segment is critical for a sustained positive re-rating of the stock.
• The recent stock underperformance of -2.5% against a rising market, coupled with a Zacks #2 (Buy) rating, could present a tactical opportunity for those confident that margin execution and strength in smaller segments can overcome the top-line growth challenges.
• Consider that the primary risk is concentrated in the core pharmaceutical business, where both revenue and profit missed estimates, potentially signaling ongoing margin pressure or market share challenges that could continue to weigh on overall results.